Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy von TEN TIJE, Albert J, VERWEIJ, Jaap, LOOS, Walter J, SPARREBOOM, Alex

Volltext

Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer von Franken, M.D, van Rooijen, E.M, May, A.M, Koffijberg, H, van Tinteren, H, Mol, L, ten Tije, A.J, Creemers, G.J, van der Velden, A.M.T, Tanis, B.C, Uyl-de Groot, C.A, Punt, C.J.A, Koopman, M, van Oijen, M.G.H

Volltext

Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5 von Graff, Julie Nicole, Antonarakis, Emmanuel S., Hoimes, Christopher J., Tagawa, Scott T., Hwang, Clara, Kilari, Deepak, Ten Tije, AJ, Omlin, Aurelius Gabriel, McDermott, Raymond S., Vaishampayan, Ulka N., Elliott, Anthony, Wu, Helen, Kim, Jeri, Schloss, Charles, De Bono, Johann S.

Volltext

Abstract P6-17-19: What to do with trastuzumab therapy after achieving radiological complete remission (rCR) in HER2+ metastatic breast cancer (MBC)? von Steenbruggen, TG, Bouwer, NI, Smorenburg, CH, Rier, HN, Jager, A, Beelen, KJ, ten Tije, AJ, de Jong, PC, Drooger, JC, Holterhues, C, Horlings, HM, Sanders, J, Levin, M-D, Sonke, GS

Volltext

Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly von TEN TIJE, Albert J, VERWEIJ, Jaap, CARDUCCI, Michael A, GRAVELAND, Wilfried, ROGERS, Theresa, PRONK, Tatjana, VERBRUGGEN, M. P, DAWKINS, Fitzroy, BAKER, Sharyn D

Volltext

Effect of Cytochrome P450 3A4 Inhibition on the Pharmacokinetics of Docetaxel von Engels, Frederike K., Tije, Albert J., Baker, Sharyn D., Lee, Carlton K. K., Loos, Walter J., Vulto, Arnold G., Verweij, Jaap, Sparreboom, Alex

Volltext

Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients von BAKER, Sharyn D, VAN SCHAIK, Ron H. N, MCGUIRE, William P, DAWKINS, Fitzroy, GELDERBLOM, Hans, VERWEIJ, Jaap, SPARREBOOM, Alex, RIVORY, Laurent P, TEN TIJE, Albert J, DINH, Kimberly, GRAVELAND, Wilfried J, SCHENK, Paul W, CHARLES, Kellie A, CLARKE, Stephen J, CARDUCCI, Michael A

Volltext

Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia von Baker, Sharyn D., Li, Jing, Tije, Albert J., Figg, William D., Graveland, Wilfried, Verweij, Jaap, Sparreboom, Alex

Volltext

Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements von Hooker, AC, Ten Tije, AJ, Carducci, MA, Weber, J, Garrett‐Mayer, E, Gelderblom, H, Mcguire, WP, Verweij, J, Karlsson, MO, Baker, SD

Volltext

Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer von Smorenburg, C.H, ten Tije, A.J, Verweij, J, Bontenbal, M, Mross, K, van Zomeren, D.M, Seynaeve, C, Sparreboom, A

Volltext

Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial von ten Tije, A.J, Smorenburg, C.H, Seynaeve, C, Sparreboom, A, Schothorst, K.L.C, Kerkhofs, L.G.M, van Reisen, L.G.P.M, Stoter, G, Bontenbal, M, Verweij, J

Volltext

Practice variation in Sentinel Lymph Node Biopsy for melanoma patients in different geographical regions in the Netherlands von Verstijnen, J., Damude, S., Hoekstra, H.J., Kruijff, S., ten Tije, A.J., Louwman, W.J., Bastiaannet, E., Stuiver, M.M.

Volltext

PD07-07: Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): Fir... von Lam, SW, de Groot, SM, Honkoop, AH, Jager, A, ten Tije, AJ, Bos, MMEM, Linn, SC, van den, Bosch J, Nortier, JWR, Braun, JJ, de Graaf, H, Portielje, JEA, Los, M, Gooyer, DD, van Tinteren, H, Boven, E

Volltext

A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study) von Corrie, P.G., Terheyden, P., Tije, A.J., Herbst, R., Jansen, R., Marples, M., Debus, D., Marconcini, R., Blasinska‐Morawiec, M., Freivogel, K., Munson, M.L.G., Goodman, G.R., Hsu, J.J., Sadetsky, N., Colburn, D., Rutkowski, P.

Volltext

Reply to “Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer)” by L. D... von Smorenburg, C. H., ten Tije, A. J.

Volltext

Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: A population-based analysis von Latenstein, A.E.J., Mackay, T.M., Creemers, G.J., van Eijck, C.H.J., de Groot, J.W.B., Mohammad, N Haj, Homs, M.Y.V., van Laarhoven, H.W.M., Molenaar, I.Q., Tije, AJ ten, de Vos-Geelen, J., Besselink, M.G., van der Geest, L.G.M., Wilmink, J.W.

Volltext

Phase I and Pharmacokinetic Study of Brostallicin (PNU-166196), a New DNA Minor-Groove Binder, Administered Intravenously Every 3 Weeks to Adult Patients with Metastatic Cancer von TEN TIJE, Albert J, VERWEIJ, Jaap, STOTER, Gerrit, PLANTING, Andre S. T, DE JONGE, Maja J. A, SPARREBOOM, Alex, VAN DER GAAST, Ate, FOWST, Camilla, FIORENTINI, Francesco, TURSI, Jennifer, ANTONELLINI, Alessandro, MANTEL, Marijke, HARTMAN, Carla M

Volltext

Disposition of polyoxyethylated excipients in humans: Implications for drug safety and formulation approaches von Tije, Albert J., Loos, Walter J., Verweij, Jaap, Baker, Sharyn D., Dinh, Kimberly, Figg, William D., Sparreboom, Alex

Volltext

Limited cerebrospinal fluid penetration of docetaxel von ten Tije, Albert J, Loos, Walter J, Zhao, Ming, Baker, Sharyn D, Enting, Roelien H, van der Meulen, Hans, Verweij, Jaap, Sparreboom, Alex

Volltext

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel von Loos, Walter J, Szebeni, Janos, ten Tije, Albert J, Verweij, Jaap, van Zomeren, Desirée M, Chung, Kyu-nung, Nooter, Kees, Stoter, Gerrit, Sparreboom, Alex

Volltext